AGILUS DIAGNOSTICS LIMITED FILES DRHP WITH SEBI

Bhubaneswar: Diagnostic service provider Agilus Diagnostics Limited (“The Company”), files its Draft Red Herring Prospectus (“DRHP”) with market regulator Securities and Exchange Board of India (“SEBI”).

The Company plans to raise funds through initial public offerings (“IPO”) of Equity Shares (face value ₹ 10 each). The total offer comprises of offer for sale up to 14,233,964 Equity Share by Selling Shareholders. (“The Offer”)

The Company is the largest diagnostics service provider in terms of number of laboratories and the second largest in terms of revenue from operations in India as of and for the financial year ended March 31, 2023 (Source: CRISIL Report)

The Offer for Sale by selling shareholders included up to 2,985,075 Equity Shares by International Finance Corporation l, up to 7,462,700 Equity Shares by NYLIM Jacob Ballas India Fund III LLC and up to 3,786,189 Equity Shares by Resurgence PE Investments Limited. (The “Offer for Sale”).

The Equity Shares that will be offered through the Red Herring Prospectus are proposed to be listed on the BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”).

ICICI Securities Limited, Axis Capital Limited & Citigroup Global Markets India Private Limited are the Book Running Lead Managers to the issue.

The Company offers diagnostics testing services (routine and specialized tests), wellness and preventive care packages, hospital laboratory management services and clinical research trial testing services. As of March 31, 2023, we had a network of 413 laboratories out of which 43 laboratories were accredited by National Accreditation Board for Testing and Calibration Laboratories (“NABL”), which according to the CRISIL Report, is the largest network of NABL accredited laboratories in India, as of March 31, 2023.